Disc Medicine to Submit NDA for Bitopertin in EPP in October 2025
Disc Medicine’s recent pre-NDA meeting with the FDA regarding bitopertin for erythropoietic protoporphyria (EPP) has yielded positive feedback, paving...
Amneal Q2 2025 Financial Results
Amneal Pharmaceuticals projects robust second-quarter 2025 results, with net revenue anticipated between $720 million and $730 million, representing a...
Biogen’s $2B Investment in NC Research Triangle Park
Biogen has doubled down on its commitment to North Carolina’s Research Triangle Park (RTP), announcing a $2 billion investment...
iTeos Therapeutics Acquired by Concentra Biosciences for $10.047 Per Share + CVR
Iteos Therapeutics, a clinical-stage biotech company, is being acquired by Concentra Biosciences for $10.047 per share in cash, plus...
Monte Rosa Doses First Subjects in Phase 1 Study of MRT-8102
Monte Rosa Therapeutics has initiated a Phase 1 trial for MRT-8102, a novel molecular glue degrader (MGD) targeting NEK7...
Widaplik™ Tablets US Licensing Deal: Azurity & George Medicines Sign
George Medicines has licensed Widaplik (telmisartan, amlodipine, and indapamide) to Azurity Pharmaceuticals for exclusive commercialization in the US. This...
NewGen Subsidiary & UAE Developer Sign Landmark MoU
NewGenIVF Group Limited is taking a calculated leap beyond its core fertility services business through a strategic land development...
Move Fibro Forward: Tonix Pharmaceuticals’ New Campaign
Tonix Pharmaceuticals has launched the “Move Fibro Forward” campaign, an initiative designed to raise awareness and support for individuals...
BioXcel Submits Meeting Package for Potential Label Expansion of Igalmi
BioXcel Therapeutics is pursuing a label expansion for its sublingual film Igalmi (dexmedetomidine) to permit outpatient use for acute...
Darolutamide Approved in EU for Advanced Prostate Cancer
The European Commission has granted marketing authorization for darolutamide, an oral androgen receptor inhibitor (ARI), in combination with androgen...